Information on the Target

Synendos Therapeutics is a biopharmaceutical company based in Basel, Switzerland, focused on restoring the natural functioning of the endocannabinoid system to treat Central Nervous System (CNS) disorders. The company aims to develop first-in-class inhibitors that target a newly identified drug mechanism in the endocannabinoid system, potentially addressing unmet medical needs in CNS treatment.

Incorporated in April 2019, Synendos is the result of research conducted over a decade at the University of Bern and aims to create therapies for various CNS disorders including anxiety, mood, and stress-related conditions through selective endocannabinoid reuptake inhibitors (SERIs).

Industry Overview in Switzerland

The pharmaceutical and biotechnology industries in Switzerland are globally recognized for their innovation, quality, and regulatory environment. Switzerland has established itself as a hub for biopharmaceutical research and development, benefiting from a highly skilled workforce, sophisticated research institutions, and substantial investments in innovation. The ecosystem is further bolstered by strong cooperation between academia and industry, producing cutting-edge therapies that address complex medical challenges.

In recent years, there has been a marked increase in focus on neurological disorders, reflecting a growing awareness of mental health issues and their impact on society. Swiss biotech companies are actively engaged in developing novel treatments that leverage advanced platforms, including gene therapy and biologics, to address various CNS disorders.

Government support through funding programs, such as the Eurostars initiative, has also played a crucial role in promoting research and development among small and medium-sized enterprises (SMEs), prioritizing the development of innovative solutions to improve patient outcomes.

The combination of a robust investment landscape, supportive policies, and a culture of innovation positions Switzerland favorably to continue leading in the biopharmaceutical sector, particularly in the development of therapeutics that target CNS conditions.

The Rationale Behind the Deal

This extension of Synendos' Series A financing, now totaling CHF 24 million, is aimed at completing preclinical development and advancing their lead drug candidate through crucial safety and proof-of-concept clinical trials. The collaboration with Ysios Capital, alongside existing investors Kurma Partners and Sunstone Life Science Ventures, underscores the confidence that these seasoned investors have in Synendos’ innovative therapeutic approach.

Moreover, securing the prestigious Eurostars grant enables Synendos to expand its preclinical studies for post-traumatic stress disorder (PTSD), showcasing the efficacy of their technology in potentially addressing significant unmet medical needs in the CNS space.

Information about the Investor

Ysios Capital is a leading Spanish venture capital firm specializing in private equity financing for early and mid-stage life science companies. Founded in 2008, the firm manages over €350 million across three dedicated funds, with a strong focus on supporting the development of disruptive therapeutic innovations that enhance patient care. Ysios Capital's team consists of experienced professionals with a proven track record in building successful biotech companies.

Ysios Capital’s involvement in Synendos aligns with its investment strategy targeting therapeutics that address clear unmet medical needs. The firm's expertise will be crucial as Synendos develops its novel drug technologies and advances towards clinical milestones.

View of Dealert

The investment in Synendos Therapeutics appears to be a prudent move, given the company's innovative approach to CNS disorders and its promising early research. By leveraging a novel mechanism of action through SERIs, Synendos addresses a crucial gap in the market for safer and more effective treatments for mental health conditions, which is of increasing priority in global health.

With the additional funding of CHF 24 million, Synendos is poised to advance its preclinical development and start IND enabling studies, which are critical next steps in the journey toward clinical trials and regulatory approval. This alignment with potential future funding avenues and grants further mitigates risk for investors.

The appointment of Professor Jutta Heim as Chair to the Board adds a strong scientific and leadership component, enhancing Synendos' strategic position. Her extensive experience in pharmaceutical research and leadership roles positions the company favorably as it navigates the complexities of biotech development.

In conclusion, considering the current trends in CNS therapeutic development, coupled with a solid backing from reputable investors and significant grant support, the investment in Synendos is promising and could yield substantial returns in the burgeoning field of mental health care.

View Original Article